ADB-FUBHQUCA

ADB-FUBHQUCA is a synthetic cannabinoid receptor agonist that has been sold as a designer drug, first reported in 2022.^[1] It is related to the previously reported compound ADB-FUBICA but with the central indole ring system expanded to a 1,4-dihydroquinoline structure. This breaks the aromaticity of the ring system, and ADB-FUBHQUCA is relatively low in potency compared to related compounds where the aromatic core is retained.^{[2][3][4][5][6][7][8][9][10][11][12][13]}

ADB-FUBHQUCA

Identifiers
IUPAC name (S)-N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1,4-dihydroquinoline-3-carboxamide
PubChem CID	165361603
CompTox Dashboard (EPA)	DTXSID201342574
Chemical and physical data
Formula	C23H26FN3O2
Molar mass	395.478 g·mol−1
3D model (JSmol)	Interactive image
SMILES NC(=O)[C@@H](NC(=O)C=1Cc2ccccc2N(C=1)Cc1ccc(F)cc1)C(C)(C)C
InChI InChI=1S/C23H26FN3O2/c1-23(2,3)20(21(25)28)26-22(29)17-12-16-6-4-5-7-19(16)27(14-17)13-15-8-10-18(24)11-9-15/h4-11,14,20H,12-13H2,1-3H3,(H2,25,28)(H,26,29) Key:WEFDGWANUSMUJL-UHFFFAOYSA-N

See also

• ADB-FUBIATA
• S-444,823
• S-777,469
• SER-601